External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul>
<li>Clarity have announced that PROPELLER, their Phase I diagnostic trial assessing 64Cu-SAR- bisPSMA in detecting prostate cancer, has met all primary and secondary endpoints.</li>
<li>As outlined in our most recent note, this trial represents a significant de-risking point for the company, validating the use of their SAR copper platform, and, transitioning the company into a pivotal trial stage in 2023, with Clarity confirming start of a pivotal Phase III for this diagnostic asset next year.</li>
<li>Full data on 64Cu SAR-bisPSMA will be released at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Symposium in February 2023.</li>
</ul>
<p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>


Clarity have announced that PROPELLER, their Phase I diagnostic trial assessing 64Cu-SAR- bisPSMA in detecting prostate cancer, has met all primary and secondary endpoints.
As outlined in our most recent note, this trial represents a significant de-risking point for the company, validating the use of their SAR copper platform, and, transitioning the company into a pivotal trial stage in 2023, with Clarity confirming start of a pivotal Phase III for this diagnostic asset next year.
Full data on 64Cu SAR-bisPSMA will be released at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Symposium in February 2023.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - Propulsion of Value with Positive Topline Results